REILLY FINANCIAL ADVISORS, LLC - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 98 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
REILLY FINANCIAL ADVISORS, LLC ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q4 2021$5,0000.0%2,0000.0%0.00%
Q3 2021$5,000
-16.7%
2,0000.0%0.00%
Q2 2021$6,000
+20.0%
2,0000.0%0.00%
Q1 2021$5,000
+25.0%
2,0000.0%0.00%
Q4 2020$4,000
+100.0%
2,0000.0%0.00%
Q3 2020$2,0000.0%2,0000.0%0.00%
Q2 2020$2,0000.0%2,0000.0%0.00%
Q1 2020$2,0000.0%2,0000.0%0.00%
Q4 2019$2,0000.0%2,0000.0%0.00%
Q3 2019$2,0002,0000.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q1 2020
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$52,403,2283.69%
Raffles Associates 1,536,946$2,305,4193.14%
Defender Capital, LLC. 5,136,085$7,704,1282.69%
Prescott General Partners LLC 1,851,851$2,777,7770.22%
DAFNA Capital Management LLC 140,000$210,0000.06%
Beirne Wealth Consulting Services, LLC 45,000$67,5000.05%
CTC Capital Management, LLC 14,100$21,1500.04%
Diametric Capital, LP 50,875$76,3130.04%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 781,766$1,172,6490.03%
One68 Global Capital, LLC 13,377$20,0660.03%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders